To study the transcriptional profile of CD8+ CAR-T cells, we selected four additional patients with durable persistence of CAR-T cells following infusion of CD8+ CAR-T cells manufactured from either TCM cells or bulk CD8+ T cells for NHL (n = 2) or chronic lymphocytic leukemia (CLL, n = 2), respectively (Supplementary Table 1). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.